{"entity":{"id":"nct06380751","kind":"trial","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","aka":["EvoPAR-Breast01"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06380751 as recruiting, last updated 2026-09-02. Enrolment is 788 planned participants, an estimate. Interventions: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane. Primary measures include Progression-Free Survival (Arm 1 vs arm 2). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06380751","url":"https://clinicaltrials.gov/study/NCT06380751"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":["parp"],"drugs":["saruparib","camizestrant","abemaciclib","ribociclib","palbociclib","fulvestrant"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06380751","phase":"3","setting":"A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)","sponsor":"AstraZeneca","participation":[{"nct":"NCT06380751","source":"https://clinicaltrials.gov/study/NCT06380751","fetchedAt":"2026-10-07T16:54:36.402Z","studySha256":"d8fb1dea88574c08fe4ae4b307bc164bd05661710f8c0f06e672b02e64dd293e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-02","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":788,"enrolmentType":"ESTIMATED","siteCount":306,"recruitingSiteCount":239,"countries":["Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Chile","China","Czechia","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","Peru","Poland","Portugal","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-08-01","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06380751/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}